BLRX - BioLineRx Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8239
-0.0121 (-1.4474%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.8360
Open0.8400
Bid0.8201 x 100
Ask0.8239 x 8200
Day's Range0.8132 - 0.8447
52 Week Range0.8000 - 1.3400
Volume210,764
Avg. Volume291,909
Market Cap87.057M
Beta0.02
PE Ratio (TTM)N/A
EPS (TTM)-0.2710
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)
    Zacks21 days ago

    Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)

    Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)

  • ACCESSWIRE28 days ago

    Wired News – vTv Therapeutics Completed Phase-1b Study Evaluating TTP399 for Treatment of Type-1 Diabetes

    Stock Monitor: BioLine Rx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on vTv Therapeutics Inc. (NASDAQ: VTVT ). If you ...

  • PR Newswire29 days ago

    BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors

    TEL AVIV, Israel, March 26, 2018 /PRNewswire/ --  BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of AGI-134, a novel immunotherapy compound, for the treatment of solid cancer tumors. This patent, when issued, will be valid until May 2035 with a possibility of up to five years patent term extension. Additional corresponding patent applications for AGI-134 are pending in Europe, Japan, China, Canada, Australia and Israel.

  • PR Newswirelast month

    BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference

    TEL AVIV, Israel , March 14, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...

  • ACCESSWIRE2 months ago

    Bioline RX Ltd Sponsored ADR to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018, at 10:00 AM Eastern ...

  • PR Newswire2 months ago

    BioLineRx Reports Year End 2017 Financial Results

    TEL AVIV, Israel , March 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...

  • PR Newswire2 months ago

    BioLineRx to Report Annual 2017 Results on March 6, 2018

    Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel, Feb. 27, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on ...

  • PR Newswire3 months ago

    BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13

    TEL AVIV, Israel , Feb. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...

  • PR Newswire3 months ago

    BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells

    BioLineRx Ltd. (BLRX) (BLRX) (BLRX.TA) a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the publication of data showing that BL-8040, its lead oncology platform, augments the ability of the immune system to fight cancer by increasing the infiltration of anti-tumor-specific T-cells into the tumor microenvironment (TME), resulting in decreased tumor growth and prolonged survival in a murine model of cancer. Results of the study will be presented as a poster titled "CXCR4 Antagonist (BL-8040) Enhances Antitumor Effects by Increasing Tumor Infiltration of Antigen-specific Effector T-cells" (Abstract 73) on January 25, 2018 at the ASCO-SITC Clinical Immuno-Oncology Symposium, being held January 25-27, 2018, in San Francisco, CA. In the preclinical study, a murine model of cancer was used to assess the effects of BL-8040 in combination with a cancer vaccine that primes the immune system against the tumor.

  • PR Newswire3 months ago

    BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical Studies

    BioLineRx Ltd. (BLRX) (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that AGI-134, an immunotherapy compound in development for the treatment of multiple solid tumors, demonstrated successful results in two pre-clinical melanoma studies. Results of these studies will be presented as a poster titled "Intratumoral Administration of the Alpha-Gal Glycolipid AGI-134 to Induce Tumor Regression in a Mouse Model of Melanoma" (Abstract 68) on January 25, 2018 at the ASCO-SITC Clinical Immuno-Oncology Symposium, being held January 25-27, 2018, in San Francisco, CA. The ability of intratumorally injected AGI-134 to induce regression of established primary tumors was assessed in two murine melanoma models.

  • BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa
    Zacks3 months ago

    BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa

    BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.

  • PR Newswire3 months ago

    BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer

    TEL AVIV, Israel, Jan. 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today partial results from the monotherapy portion of BL-8040's Phase 2a COMBAT study showing that BL-8040 increases infiltration of T cells into the tumor in patients with metastatic pancreatic cancer. The data will be presented as a poster titled "Evaluation of Pharmacodynamic Biomarkers in Patients with Metastatic Pancreatic Cancer Treated with BL-8040, a Novel CXCR4 Antagonist (Abstract 276)" at the ASCO 2018 Gastrointestinal Cancers Symposium, on January 19, 2018 in San Francisco, CA.

  • ACCESSWIRE4 months ago

    Blog Exposure - BioLine Declares Initiation of Phase-3 GENESIS Trial in Stem-Cell Mobilization Therapy BL-8040

    LONDON, UK / ACCESSWIRE / December 26, 2017 / Active-Investors.com has just released a free research report on BioLine Rx Ltd (NASDAQ: BLRX ) ("BioLineRx"). If you want access to this report ...

  • Stock Update (NASDAQ:BLRX): Bioline RX Ltd Sets in Motion Phase 3 Trial for Stem Cell Mobilization Therapy BL-8040
    SmarterAnalyst4 months ago

    Stock Update (NASDAQ:BLRX): Bioline RX Ltd Sets in Motion Phase 3 Trial for Stem Cell Mobilization Therapy BL-8040

    Bioline RX Ltd (NASDAQ:BLRX) is officially turning its Phase 3 GENESES clinical trial's wheels, with the Israeli drug maker revealing today the launch of evaluating its stem-cell mobilization asset BL-8040. In the initiation of the clinical trial, BiolineRx will be investigating the mobilization of hematopoietic stem cells by BL-8040 against a placebo, on top of granulocyte colony-stimulating factor (G-CSF), a powerful inducer of hematopoietic stem cell (HSC) mobilization from the bone marrow into the bloodstream.

  • PR Newswire4 months ago

    BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today initiation of the Phase 3 GENESIS clinical trial, in which BL-8040 will be compared to placebo, on top of granulocyte colony-stimulating factor (G-CSF), for the mobilization of hematopoietic stem cells (HSCs) used for autologous transplantation in multiple myeloma patients. The GENESIS study is a Phase 3, randomized, placebo-controlled, multicenter study, evaluating the safety, tolerability and efficacy of BL-8040 and G-CSF, compared to placebo and G-CSF, for the mobilization of HSCs for autologous transplantation in multiple myeloma patients.

  • PR Newswire5 months ago

    BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY

    TEL AVIV, Israel, Dec. 5, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today hosts its investor breakfast meeting at the Convene Conference Center near Grand Central in New York, NY. Philip Serlin, Chief Executive Officer of BioLineRx, stated, "This annual event gives us the opportunity to directly meet with our investors for updates on our progress:  steady advancements on our multiple clinical programs in stem cell mobilization, combination immunotherapies and acute myeloid leukemia (AML), as well as our new and novel immuno-oncology therapy.

  • PR Newswire5 months ago

    BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive overall survival data from the long-term follow-up part of the Phase 2a trial of BL-8040 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML). The results demonstrate that the combination of BL-8040 with high-dose Ara-C (HiDAC) in this difficult-to-treat patient population significantly improved overall survival, compared with historical data of HiDAC monotherapy. The long-term survival results from the Phase 2a study derive from the expansion phase of the study, which included 16 patients (out of 42 total patients enrolled in the study).

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Trending Tickers: BioLineRx Ltd. and Opko Health, Inc.

    NEW YORK, NY / ACCESSWIRE / November 29, 2017 / U.S. markets closed at record highs Tuesday as the U.S. moved one stepped closer to a tax reform after a recent Senate vote. The Dow Jones Industrial Average ...

  • PR Newswire5 months ago

    BioLineRx Reports Third Quarter 2017 Financial Results

    TEL AVIV, Israel , Nov. 21, 2017 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for ...

  • PR Newswire5 months ago

    BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that an abstract with partial results from the monotherapy portion of BL-8040's Phase 2a COMBAT study in pancreatic cancer was accepted for presentation at the ASCO 2018 Gastrointestinal Cancers Symposium, to take place January 18-20, 2018 in San Francisco, CA. The Phase 2a study, named the COMBAT study, is an open-label, multicenter, single-arm trial designed to evaluate the safety and efficacy of the combination of BL-8040 and KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., (known as MSD outside the United States and Canada), in up to 30 subjects with metastatic pancreatic adenocarcinoma.

  • PR Newswire5 months ago

    BioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New York

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 5, 2017 at the Convene Conference Center near Grand Central in New York, NY.

  • PR Newswire5 months ago

    BioLineRx to Report Third Quarter 2017 Results on November 21, 2017

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for the quarter ended September 30, 2017 on Tuesday, November 21, 2017, before the U.S. markets open. The Company will host a conference call on Tuesday, November 21, 2017 at 10:00 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer, and David Malek, Chief Business Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website.

  • PR Newswire7 months ago

    BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the initiation of a Phase 1b/2 trial for BL-8040 in combination with atezolizumab (TECENTRIQ®), an anti-PDL1 cancer immunotherapy from Genentech, a member of the Roche Group. The trial, known as the BATTLE study (NCT03154827), will focus on the maintenance treatment of patients with intermediate and high-risk acute myeloid leukemia (AML) who have achieved a complete response (CR) following induction and consolidation therapy.

  • PR Newswire8 months ago

    BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

    BioLineRx Ltd. (BLRX)(BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin, and its Chief Business Officer, David Malek, will present a company update at the 19th Annual Rodman & Renshaw Global Investment Conference at the Lotte New York Palace Hotel in New York City. BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology.

  • BioLineRx Moves a Regulatory Submission for BL-8040 Trial
    Zacks8 months ago

    BioLineRx Moves a Regulatory Submission for BL-8040 Trial

    BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.